ReviewRecent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
Introduction
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions characterized histologically by hepatic steatosis in individuals without significant alcohol consumption and negative viral, congenital, and autoimmune liver disease markers. Hepatic lipid accumulation results from an imbalance between lipid availability (from circulating lipid uptake or de novo lipogenesis) and lipid disposal (via fatty acid oxidation or triglyceride-rich lipoprotein secretion) and eventually triggers lipoperoxidative stress and hepatic injury. NAFLD is now considered the hepatic manifestation of the metabolic syndrome and has insulin resistance as its hallmark [1], [2]. Previously thought to be benign, it recently became clear NAFLD encompasses a spectrum of liver disease ranging from pure, benign fatty liver to the more severe nonalcoholic steatohepatitis (NASH), a condition that may progress to cirrhosis in up to 25% of patients [3]. Furthermore, NAFLD is emerging as a risk factor for diabetes and cardiovascular disease, independently of insulin resistance, metabolic syndrome, plasma lipid levels and other traditional risk factors [4]. The specific origin of the lipids, mainly triacylglycerol (TAG), accumulating in liver has been unravelled by recent kinetic studies, and identifying the origin of the accumulated TAG and non-esterified fatty acids (NEFA) in the livers of patients with NAFLD may direct prevention and treatment of this condition.
Section snippets
Mechanisms of hepatic lipid accumulation: a kinetic perspective
From a kinetic standpoint, hepatic steatosis develops when there is an imbalance in which fatty acid uptake and de novo synthesis exceed oxidation and resecretion. The sources of fatty acids potentially contributing to fatty liver include (Fig. 1):
- –
peripheral fat stored in adipose tissue that is delivered to the liver by way of the plasma NEFA pool (pathway 1). Insulin resistance is associated with dysregulation of adipose-derived fatty acid flux in the fasting state, and strong evidence exists
Hepatic non-esterified fatty acid uptake
As summarized above, circulating NEFA, either of dietary or endogenous origin, provide most of the hepatic lipid content in NAFLD. It is therefore essential to gain insight into mechanisms regulating hepatic NEFA uptake from the circulation. Ravikumar et al. observed, by using 13C magnetic resonance spectroscopy, an accelerated postprandial incorporation of dietary fatty acids (FAs) into liver TAG in patients with type 2 diabetes mellitus (4 h vs. 6 h), as well as a 50% higher FA accumulation
Hepatic de novo lipogenesis
According to recent kinetic data,, whereas DNL is only elevated postprandially in healthy subjects (20–30% VLDL–TAG), in NAFLD DNL is elevated in fasting conditions and lacks further postprandial elevation [5], [7], [79]. These observations support the concept of a paradoxically sustained elevation in hepatic lipogenic activity in NAFLD [80]. The regulation of hepatic lipogenesis involves a complex network of nuclear receptors, co-ordinately regulating enzymes involved in different steps of
Hepatic fatty acid oxidative pathways
Different hepatic FA oxidative pathways involved in the pathogenesis of NAFLD have been the subject of several recent reviews and these will be reviewed here briefly [294], [295], [296]. Most FA are metabolized through β-oxidation, which occurs mainly in mitochondria, but also in peroxisomes. A third FA metabolizing pathway is ω-oxidation by members of the cytochrome P450 4A in the endoplasmic reticulum (microsomes). The extramitochondrial FA oxidative pathways become more important in
Regulation of hepatic VLDL assembly and secretion
Recent kinetic studies have pointed out that hepatic triglyceride-rich lipoprotein secretion rate in NAFLD is actually increased in absolute terms, as in other insulin resistant conditions, but is inadequate to match the increased TAG availability in the liver: compared to insulin resistant subjects without a significant liver fat accumulation, subjects with NAFLD failed to further increase VLDL-Tg secretion rate when hepatic Tg infiltration exceeded 10% suggesting the liver of these subjects
Concluding remarks
As it can be seen from this discussion, the pathogenesis of hepatic fat accumulation is very complex and partially understood. Although the excessive flood of free fatty acids to the liver has been traditionally regarded as the key component of NAFLD, little is known The role of hepatic membrane NEFA transporters has only recently emerged, and the complex network regulating de novo lipogenesis has been only partially unravelled. Given the limited efficacy and the long term safety concerns of
Acknowledgement
This work was funded in part by the Piedmont Region Funds Comitato Interministeriale per la Programmazione Economica 2008.
References (366)
- et al.
Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis
Hepatology
(2003) - et al.
The temporal pattern of de novo lipogenesis in the postprandial state
Am J Clin Nutr
(2005) - et al.
Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease
Diabetes Metab
(2003) - et al.
Apolipoprotein synthesis in nonalcoholic steatohepatitis
Hepatology
(2002) - et al.
Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease
Gastroenterology
(2008) - et al.
Role of FATP in parenchymal cell fatty acid uptake
Biochim Biophys Acta
(2004) - et al.
Lipid metabolism in hepatic steatosis
Clin Liver Dis
(2004) - et al.
Caveolin-1 deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities
J Biol Chem
(2002) - et al.
Enzymatic properties of purified murine fatty acid transport protein 4 and analysis of acyl-CoA synthetase activities in tissues from FATP4 null mice
J Biol Chem
(2005) - et al.
Fatty acid transport in Saccharomyces cerevisiae. Directed mutagenesis of FAT1 distinguishes the biochemical activities associated with Fat1p
J Biol Chem
(2002)
Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis
Gastroenterology
Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity
Gastroenterology
Long chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle
Biochim Biophys Acta
Acute regulation of fatty acid uptake involves the cellular redistribution of fatty acid traslocase
J Biol Chem
CD36: implications in cardiovascular disease
Int J Biochem Cell Biol
CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice
J Lipid Res
A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism
J Biol Chem
Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats
J Biol Chem
A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism
J Biol Chem
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass
J Biol Chem
A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway
J Biol Chem
Fatty acid binding proteins – the evolutionary crossroads of inflammatory and metabolic responses
J Nutr
Physiological properties and functions of intracellular fatty acid-binding proteins
Biochim Biophys Acta
Lipid-binding proteins modulate ligand-dependent trans-activation by peroxisome proliferator-activated receptors and localize to the nucleus as well as the cytoplasm
J Lipid Res
Thestructure of crystalline Escherichia coli- derived rat intestinal fatty acid-binding protein at 2.5-A resolution
J Biol Chem
Role of the helical domain in fatty acid transfer from adipocyte and heart fatty acid-binding proteins to membranes
J Biol Chem
Association of the A/T54 polymorphism in the intestinal fatty acid binding protein with variations in plasma lipids in the Framingham offspring study
Atherosclerosis
The polymorphism at codon 54 of the FABP2 gene increases fat absorption in human intestinal explants
J Biol Chem
Intestinal fatty acid binding protein and microsomal triglyceride transfer protein polymorphisms in French–Canadian youth
J Lipid Res
Decreased hepatic riglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene
J Biol Chem
Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes
Cell Metabolism
Microarray analysis indicates an important role for FABP5 and putative novel FABPs on a Western-type diet
J Lipid Res
Coordinate transcriptional repression of liver fatty acid-binding protein and microsomal triglyceride transfer protein blocks hepatic very low density lipoprotein secretion without hepatosteatosis
J Biol Chem
Fatty acid-binding protein (L-FABP). Gene expression is peroxisome proliferator-activated receptor-α-dependent
J Biol Chem
Activation of peroxisome proliferator-activated. Receptor-α Increases the expression and activity of microsomal triglyceride transfer protein in the liver
J Biol Chem
Differences in the regulation of adipose tissue and liver lipogenesis by carbohydrates in humans
J Lipid Res
The endocannabinoid system in chronic liver disease
Ann Hepatol
The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
Cell
Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13
Genomics
Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER
Cell
Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1
J Clin Invest
Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with adult treatment Panel III criteria in nonobese nondiabetic subjects
Diabetes Care
Nonalcoholic fatty liver disease: from steatosis to cirrhosis
Hepatology
Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health
J Gastroen Hepatol
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
J Clin Invest
Contributions of different fatty acid sources to very low-density lipoprotein-Triacylglycerol in the fasted and fed states
J Clin Endocrinol Metab
Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes
Am J Physiol Endocrinol Metab
Endothelial-derived lipoprotein lipase is bound to postprandial triglyceride-rich lipoproteins and mediates their hepatic clearance in vivo
J Mol Med
Lipoprotein lipase expression exclusively in liver. A mouse model for metabolism in the neonatal period and during cachexia
J Clin Invest
A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids
Lipids
Cited by (560)
Lactobacillus Casei-fermented Amomum Xanthioides Mitigates non-alcoholic fatty liver disease in a high-fat diet mice model
2024, Biomedicine and PharmacotherapyAn optimized fluorescent biosensor for monitoring long-chain fatty acyl-CoAs metabolism in vivo
2024, Biosensors and BioelectronicsCucurbitacin B ameliorates AKT-driven fatty liver disease in mice by suppressing AKT/mTORC1 and LXRα/SREBP1 lipogenic pathways
2024, Journal of Functional Foods